Foralumab

Phase 2Monoclonal antibody

Foralumab is one of 28 small molecule programs targeting Secondary Progressive Multiple Sclerosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Secondary Progressive Multiple SclerosisActive, not recruiting

Multiple System AtrophyRecruiting

Secondary Progressive Multiple SclerosisPhase 2

Active, not recruiting

Multiple System AtrophyPhase 2

Recruiting

Competition

Competitive Landscape

20 competitors in Multiple System Atrophy

#DrugCompanyPhaseTrials

Rifadin

Northera

Rilutek

AAzurity Pharmaceuticals

Sudafed

Lu AF95245

1 6

TEV-56286

Teva

Phase 2

2 7

Foralumab

TTiziana Life Sciences LTD

Phase 2

1 8

Bendopa

MMerz North America, Inc.

Preclinical

1 9

ATH434

AAlterity Therapeutics

Phase 2

2 10

Human Dopaminergic Progenitor Cells

IiRegene Therapeutics Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Secondary Progressive Multiple Sclerosis

NCT06292923

Phase 2Recruiting

Alzheimer's Disease

NCT06489548

Q2 2027

Phase 2Recruiting

Multiple System Atrophy

NCT06868628

Clinical

Trials by Indication[1]

Secondary Progressive Multiple Sclerosis2 trials

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Recruiting·TTiziana Life Sciences LTD·Phase 2·NCT06890923·55 enrolled

A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Active, not recruiting·TTiziana Life Sciences LTD·Phase 2·NCT06292923·54 enrolled

Antibody1 trial

Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM

Withdrawn·TTiziana Life Sciences LTD·Phase 2·NCT03291249

COVID-191 trial

In-patient COVID-19 Study of Intranasal Foralumab

Withdrawn·TTiziana Life Sciences LTD·Phase 2·NCT04983446

Crohn's Disease1 trial

A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease

Withdrawn·TTiziana Life Sciences LTD·Phase 1·NCT05028946

Oral1 trial

Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients

Available·TTiziana Life Sciences LTD··NCT06802328

3 more indications

Alzheimer's Disease1 trial

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

Recruiting·—·Phase 2·NCT06489548·16 enrolled

Immune1 trial

Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers

Completed·TTiziana Life Sciences LTD·Phase 1·NCT06879067·27 enrolled

Multiple System Atrophy1 trial

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

Recruiting·TTiziana Life Sciences LTD·Phase 2·NCT06868628·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Foralumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Foralumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Foralumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tiziana Life Sciences LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: TTiziana Life Sciences LTD

Foralumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Trials by Indication[1]

Secondary Progressive Multiple Sclerosis2 trials

Antibody1 trial

COVID-191 trial

Crohn's Disease1 trial

Oral1 trial

Alzheimer's Disease1 trial

Immune1 trial

Multiple System Atrophy1 trial

References

Drug Info

Quick Facts

Related News